Regeneron Pharmaceuticals Inc. (REGN)
Last updated: 2026-11-19 02:27:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Summary
Regeneron Pharmaceuticals Inc. (REGN) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $945.39, with a market capitalization of $98.52B and a P/E ratio of 20.57. Over the past 52 weeks, its price has ranged from $591.52 to $991.73. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$98.52B | |
$957.25 | |
$971.75 | |
$943.23 | |
$957.76 | |
560.28K | |
803.79K | |
20.57 | |
$991.73 | |
$591.52 | |
0.39% | |
2026-09-30 |
Regeneron Pharmaceuticals Inc. (REGN) Latest Closing Stock Price
Regeneron Pharmaceuticals Inc. (REGN) last closed at $945.39 as of 2026-11-19 01:00:00, down 1.29% ($12.40) from the previous close of $957.76.
During the latest regular trading session, REGN traded between $943.23 and $971.75, with a volume of 560.28K shares. The closing price was near the lower end and near the upper end of its 52-week range.
Regeneron Pharmaceuticals Inc. (REGN) 7-Day Stock Price Change
Over the past seven days, Regeneron Pharmaceuticals Inc. (REGN) moved from $919.96 to $945.39, representing a gain of 2.76% ($25.43).
The stock traded between $898.29 and $981.55 during the period. The latest price is near the middle of the 7-day range, indicating moderate upward.
The average daily volume was 945.52 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
REGN 52-Week Price Position
Position in Range: 88.4%
REGN is currently trading at $945.39, placing it 88.4% of the way from its 52-week low of $591.52 to its 52-week high of $991.73. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is Regeneron Pharmaceuticals Inc. (REGN)?
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
Regeneron Pharmaceuticals Inc. Information
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 15,410 |
| CEO | Leonard S. Schleifer |
| Founded | 1988 |
| Exchange | NASDAQ |
| Company Website |
REGN Stock Events
View the latest dividend and stock split events for Regeneron Pharmaceuticals Inc.
Dividend | |
|---|---|
| Ex-Dividend Date | Nov 20, 2026 |
| Payment Date | Dec 3, 2026 |
| Dividend Per Share | $0.94 |
REGN News
Latest news related to Regeneron Pharmaceuticals Inc. and REGN stock.
- Read Full Article
- Read Full Article
CytomX Therapeutics Announces $5M Milestone Payment From Regeneron Triggered By Preclinical Milestone In Collaboration
- Read Full Article
Biotechnology Market Companies 2027 Analysis: Amgen, Gilead, Regeneron, Vertex and Moderna Post Strong 2026 Results as Billion-Dollar Deals Reshape a Market Headed for USD 6.34 Trillion by 2035
The global biotechnology market, valued at USD 2.02 trillion in 2026, is projected to reach USD 6.34 trillion by 2035 at a 13.61% CAGR. Leading biotech companies including Amgen, Gilead, Regeneron, Vertex, and Moderna reported strong Q3 2026 results with revenue growth ranging from 8% to 36%. The sector experienced record dealmaking activity with major acquisitions totaling tens of billions of dollars, driven by patent expiries, strong cash flows, and strategic pipeline expansion in oncology, immunology, and advanced therapies.
- Read Full Article
Regeneron Pharmaceuticals Says EC Approves Alternative, Flexible Dosing Schedule For Libtayo Across All Approved Skin, Lung And Cervical Cancer Indications
Approval introduces an extended dosing regimen of Libtayo 700 mg given every six weeks, following initial 12 weeks of treatment with Libtayo 350 mg every three weeksAlso approved is an option of reducing subsequent
- Read Full Article
Regeneron Drug Lowers Standing Heart Rate And Improves Symptoms In Heart Disease Study
Regeneron reports Phase 2 PINNACLE trial data showing baloncibart reduces standing heart rate and improves symptoms in adults with POTS.
Ways to Trade REGN at MEXC
How to Buy Regeneron Pharmaceuticals Inc. (REGN) Stock on MEXC
Eligible investors can buy real shares of Regeneron Pharmaceuticals Inc. (REGN) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is Regeneron Pharmaceuticals Inc. (REGN) stock price today?
2.Is REGN stock going up or down today?
3.What is REGN pre-market price?
4.What is REGN after-hours price?
5.Is REGN stock trading now?
6.Where does REGN sit relative to its 52-week high and low?
7.What sector is Regeneron Pharmaceuticals Inc. in?
8.What is Regeneron Pharmaceuticals Inc.'s market capitalization and where is it listed?
9.How is REGN valued in terms of P/E ratio and EPS?
10.Does Regeneron Pharmaceuticals Inc. pay a dividend?
Explore More US Stocks
Compliance Disclosure and Data Source
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to REGN, including Stocks, Tokenized Stocks, and Stock Futures.
Disclaimer
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Search Stocks
REGN Stock Calculator
Estimate the value between REGN shares and USD.
REGN Shares to USD
1.00 REGN shares = 945.391 USD
Calculations are estimates based on the latest available price and are for reference only.


